9th Annual Pharma IPR Conference 2020
BTI’s Power Ranking 2016 recognized Schiff Hardin in its top category—Clientopia®—for the firm’s work on behalf of the pharmaceutical industry.
For the second consecutive year, Schiff Hardin has been recognized as a top “Clientopia” law firm in the BTI Industry Power Rankings 2017.
Schiff Hardin Intellectual Property Practice Group Co-Leader Imron Aly has been recognized as a leading patent litigator in Illinois in the 2017 IAM Patent 1000 guide, based on outstanding feedback from peers and clients.
The Center for Biosimilars
The National Law Journal
Schiff Hardin LLP today announced the addition of Kevin M. Nelson as a partner in its rapidly growing Intellectual Property Group.
Schiff Hardin LLP has been recognized as one of the top law firms defending Abbreviated New Drug Application (ANDA) litigation in the 2017 Hatch-Waxman/ANDA Litigation Report compiled by legal data analytics firm Lex Machina.
Imron Aly and Sailesh Patel have been named Life Sciences Stars in the Hatch-Waxman Patent Litigation Practice Area by LMG Life Sciences in its 2018 guide.
Leading Lawyers Magazine – 2018 Business Edition
Schiff Hardin successfully secured a favorable outcome for our client, Fresenius Kabi USA LLC, in a patent-infringement suit filed by Hospira Inc., which paves the way for Fresenius to market a new generic drug.
Intellectual Property Practice Group Co-Leaders Imron Aly and Sailesh Patel were named Life Sciences Stars in the Hatch-Waxman Patent Litigation Practice Area by LMG Life Sciences in its 2019 guide.
Intellectual Property Practice Group Co-Leader Imron Aly has joined the advisory board for the Center for Biosimilars, an online resource for emerging pharmaceutical biotechnology that discusses the current landscape for advanced health care management with top industry thought leaders.
Biosimilars Review & Report
Biosimilars Patent and Antitrust Perspectives Virtual Panel
Schiff Hardin LLP is pleased to announce that Intellectual Property Group Co-Leader Imron Aly has been named to Crain’s Chicago Business’ Notable Minorities in Accounting, Consulting & Law list for 2020.
Intellectual Property Practice Group Co-Leaders Imron Aly and Sailesh Patel and partner Kevin Nelson were named Life Sciences Stars in the Hatch-Waxman Patent Litigation Practice Area by LMG Life Sciences in its 2020 guide.
Schiff Hardin LLP is proud to announce that the firm and four of its attorneys have been ranked in the ninth edition of IAM Patent 1000: The World’s Leading Patent Professionals, a guide that identifies top patent professionals based on 1,800 interviews with private practice and in-house professionals.
Schiff Hardin LLP is pleased to announce that the firm’s Intellectual Property Practice Group has received the Impact Case of the Year award in 2020 by LMG Life Sciences for our ground-breaking patent-infringement victory in Fresenius Kabi v. Hospira.
Managing Intellectual Property
Schiff Hardin LLP is proud to announce that the firm and four of its attorneys have been ranked in the 2021 edition of IAM Patent 1000: The World’s Leading Patent Professionals, a guide that identifies top patent professionals based on 1,800 interviews with private practice and in-house professionals.
Schiff Hardin has been ranked “Recommended” by LMG Life Sciences in the Hatch-Waxman Patent Litigation (Generic) category of its 2021 guide.
Biosimilars Review and Report
Schiff Hardin LLP is pleased to announce that four of the firm’s practice groups have been recognized in The Legal 500 United States 2021 guide, which provides a nationwide analysis of law firms that provide cutting-edge and innovative advice.
Schiff Hardin’s pharma and life sciences patent litigation team, lead by partner Imron T. Aly, recently secured a preliminary injunction in federal court.
Many companies rely on boilerplate confidentiality provisions to protect their trade secrets and other sensitive business information.
Pfizer sued Johnson & Johnson (J&J) in federal court in Pennsylvania last week, alleging anticompetitive discounts and other actions to prevent competition with J&J’s biologic Remicade.
Earlier this week, the U.S. Supreme Court unanimously held, in its first case interpreting the Biologics Price Competition and Innovation Act of 2009, Sandoz Inc. v. Amgen Inc.
Like generic drugs in the 1980s, biosimilars today face a number of regulatory, legal, scientific, and public perception obstacles to continued growth.
Schiff Hardin Product Liability & Mass Torts Blog
The Pharma Letter
In the quick pound of a gavel, the entire U.S. pharmaceutical and biologics industries were thrown into doubt after Judge Reed O’Connor of the United States District Court for the Northern District of Texas found the individual mandate of the Affordable Care Act (ACA) – and therefore the entire act – unconstitutional.
As the government shutdown stretches on, pharmaceutical companies must manage the partial shutdown of the U.S. Food and Drug Administration (FDA).
Pfizer’s recent decision not to disclose data about Enbrel’s potential to treat Alzheimer’s disease has caused much debate about drugmakers’ obligations to the public.
The U.S. Food and Drug Administration (FDA) issued a final rule last week that broadened the scope of the Biologics Price Competition and Innovation Act (BPCIA) to include large proteins, even those that could have been previously governed by the Hatch-Waxman Act.
Teva Pharmaceuticals filed suit against the United States Food and Drug Administration (FDA) alleging that its glatiramer (Copaxone) falls under the revised definition of a “biological product” and should be transitioned to the system established by the Biologics Price Competition and Innovation Act of 2009 (BPCIA).